A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Commonly but incorrectly described as an alkylating agent due to its mechanism of action (but it lacks alkyl groups).
Chemical ID:
MESH:D002945
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
[Cisplatin co-treated with acetyl-11-ketoboswellic acid] results in decreased expression of BCL2L1 protein; [Cisplatin co-treated with Quercetin] results in decreased expression of BCL2L1 protein; [Cisplatin results in decreased susceptibility to Cisplatin] which results in increased expression of BCL2L1 mRNA; [CLPTM1L mutant form results in increased susceptibility to Cisplatin] which results in decreased expression of BCL2L1 protein; [CXCL8 results in increased expression of BCL2L1 mRNA] which results in decreased susceptibility to Cisplatin; [CXCL8 results in increased expression of BCL2L1 protein] which results in decreased susceptibility to Cisplatin; [Quercetin results in increased susceptibility to Cisplatin] which results in decreased expression of BCL2L1 protein; [TNFSF10 protein co-treated with Cisplatin] results in decreased expression of BCL2L1 protein; BCL2L1 protein inhibits the reaction [CLPTM1L mutant form results in increased susceptibility to Cisplatin]; BCL2L1 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]; Cisplatin promotes the reaction [Metformin results in decreased expression of BCL2L1 protein]; Cisplatin promotes the reaction [Proadifen results in decreased expression of BCL2L1 protein]; Dexamethasone inhibits the reaction [Cisplatin results in decreased expression of BCL2L1 mRNA]; Dexamethasone inhibits the reaction [Cisplatin results in decreased expression of BCL2L1 protein]; ING4 protein promotes the reaction [Cisplatin results in decreased expression of BCL2L1 protein]; LGALS3 inhibits the reaction [Cisplatin results in increased degradation of BCL2L1 protein]; Proadifen promotes the reaction [Cisplatin results in decreased expression of BCL2L1 protein]; RELA protein mutant form inhibits the reaction [Cisplatin results in decreased expression of BCL2L1 mRNA]; RELA protein mutant form inhibits the reaction [Cisplatin results in decreased expression of BCL2L1 protein]
Cisplatin results in decreased expression of BCL2L1; Cisplatin results in decreased expression of BCL2L1 mRNA; Cisplatin results in decreased expression of BCL2L1 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [resveratrol inhibits the reaction [Cisplatin results in decreased expression of BCL2L1]]; [Cisplatin co-treated with TNF protein] results in decreased expression of BCL2L1 mRNA; [CLPTM1L mutant form results in decreased expression of BCL2L1 protein] which results in increased susceptibility to Cisplatin; erdosteine inhibits the reaction [Cisplatin results in decreased expression of BCL2L1 mRNA]; erdosteine inhibits the reaction [Cisplatin results in decreased expression of BCL2L1 protein]; IL6 gene mutant form promotes the reaction [Cisplatin results in increased expression of BCL2L1 mRNA]; IL6 gene mutant form promotes the reaction [Cisplatin results in increased expression of BCL2L1 protein]; pifithrin inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [resveratrol inhibits the reaction [Cisplatin results in decreased expression of BCL2L1]]]; resveratrol inhibits the reaction [Cisplatin results in decreased expression of BCL2L1]; SIRT1 mutant form inhibits the reaction [resveratrol inhibits the reaction [Cisplatin results in decreased expression of BCL2L1]]
